ASP Isotopes Faces Class Action Lawsuit Over Uranium Technology Misrepresentation Allegations

### ASP Isotopes Faces Legal Challenges Over Uranium Technology Allegations

ASP Isotopes Inc. finds itself at the center of a class action lawsuit initiated by Glancy Prongay & Murray LLP in the United States District Court for the Southern District of New York. The lawsuit, identified as Corredor v. ASP Isotopes Inc., claims violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. It is filed on behalf of investors who acquired the company's securities between October 30, 2024, and November 26, 2024. The allegations arise from a damning report by Fuzzy Panda Research, which accuses ASP Isotopes of misrepresenting its uranium enrichment technology and its partnership with TerraPower.

The report outlines serious concerns regarding the efficacy of ASP Isotopes' technology, asserting that it relies on outdated laser enrichment methods. A former employee of Klydon, the company from which ASP Isotopes acquired its uranium enrichment technology, reportedly expressed skepticism about its effectiveness. Additionally, experts cited in the report criticize the company’s cost estimates and timelines for developing its high assay low-enriched uranium (HALEU) facilities as misleading. The former Klydon employee stated that the projections were "delusional," raising red flags about the company's operational viability and strategic direction.

Moreover, the report claims that ASP Isotopes' agreement with TerraPower is merely a non-binding memorandum of understanding, suggesting that it was intended to exert pressure on genuine suppliers rather than signify a concrete partnership. Concerns also extend to the company's subsidiary, Quantum Leap Energy, which reportedly lacks a physical presence at its registered South African address. These allegations have prompted significant investor backlash, leading to a substantial drop in ASP Isotopes' stock price in the wake of the report's release.

In light of these developments, investors who believe they have incurred losses as a result of ASP Isotopes' alleged misrepresentations have until February 3, 2025, to apply to lead the class action lawsuit. Legal firms, including Rosen Law Firm and The Law Offices of Frank R. Cruz, are actively encouraging affected shareholders to seek recovery under federal securities laws, emphasizing that participants do not need to be actively involved in the case to be eligible for compensation.

As the legal proceedings unfold, the scrutiny on ASP Isotopes intensifies, bringing to light critical questions regarding its operational integrity and future prospects in the highly competitive uranium enrichment sector. While the company navigates this tumultuous period, its ability to respond to the allegations and reassure investors will play a pivotal role in its long-term viability within the nuclear technology landscape.